1. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
- Author
-
Amelot, Aymeric, De Cremoux, Patricia, Quillien, Véronique, Polivka, Marc, Adle-Biassette, Homa, Lehmann-Che, Jacqueline, Françoise, Laurence, Carpentier, Antoine F., George, Bernard, Mandonnet, Emmanuel, and Froelich, Sébastien
- Subjects
GENETIC mutation ,ISOCITRATE dehydrogenase ,GLIOBLASTOMA multiforme ,RETROSPECTIVE studies ,CHI-squared test ,PATIENTS ,DIAGNOSIS - Abstract
Background: A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS) are found among those IDH1/2 mutated patients. Methods: We retrospectively analyzed 207 GBM patients followed at Lariboisière Hospital (Paris) between 2005 and 2010. Clinical parameters were obtained from medical records. Mutations of IDH1/2 were analyzed in these patients, by immunohistochemistry for the R132H mutation of IDH1 and by high-resolution melting-curve analysis, followed by Sanger sequencing for IDH1 and IDH2 exon 4 mutations. Mutation rates in LTS and non-LTS groups were compared by Chi square Pearson test. Results: Seventeen patients with survival >3 years were identified (8.2% of the total series). The median overall survival in long-term survivors was 4.6 years. Subgroup analysis found that the median age at diagnosis was significantly higher for non long-term survivors (non-LTS) compared to LTS (60 versus 51 years, p <0.03). The difference in the rate of IDH mutation between non-LTS and LTS was statistically not significant (1.16% versus 5.9%, p = 0.144). Among LTS, 10 out of 16 tumors presented a methylation of MGMT promoter. Conclusions: This study confirms that long-term survival in GBM patients is if at all only weakly correlated to IDH-mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF